Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

Tahlita Zuiverloon; D Theodorescu

doi:10.1016/j.eururo.2018.12.019

Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

Tahlita Zuiverloon, D Theodorescu

Urology

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	694-694
Number of pages	1
Journal	European Urology
Volume	75
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2018.12.019
Publication status	Published - 2019

Research programs

EMC MM-03-49-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2018.12.019

http://hdl.handle.net/1765/116333

Cite this

@article{ee69185215fb4a909df98bf07803270c,

title = "Re: Genomic Differences Between {"}Primary{"} and {"}Secondary{"} Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy",

author = "Tahlita Zuiverloon and D Theodorescu",

year = "2019",

doi = "10.1016/j.eururo.2018.12.019",

language = "Undefined/Unknown",

volume = "75",

pages = "694--694",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

AU - Zuiverloon, Tahlita

AU - Theodorescu, D

PY - 2019

Y1 - 2019

U2 - 10.1016/j.eururo.2018.12.019

DO - 10.1016/j.eururo.2018.12.019

M3 - Article

C2 - 30661731

SN - 0302-2838

VL - 75

SP - 694

EP - 694

JO - European Urology

JF - European Urology

IS - 4

ER -